It can be therefore envisaged that expression of wild-type ABCA4 in iPSCs derived from well-characterized STGD patients with ABCA4 mutations and their further differentiation to RPE and photoreceptor cells could potentially elicit some clinical improvement. This evidence concerns the gene ABCA4 and severe early-childhood-onset retinal dystrophy.